Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;149(11):1011-1020.
doi: 10.1001/jamaoto.2023.2982.

Margin Assessment Methods in Oral Cavity Squamous Cell Carcinoma and Recurrence: Tumor Bed vs Resection Specimen Sampling

Affiliations

Margin Assessment Methods in Oral Cavity Squamous Cell Carcinoma and Recurrence: Tumor Bed vs Resection Specimen Sampling

Shannon S Wu et al. JAMA Otolaryngol Head Neck Surg. .

Abstract

Importance: Positive margins and margin clearance are risk factors for recurrence in oral cavity squamous cell carcinoma (OCSCC), and these features are used to guide decisions regarding adjuvant radiation treatment. However, the prognostic value of intraoperative tumor bed vs resection specimen sampling is not well defined.

Objective: To determine the prognostic implications of intraoperative margin assessment methods (tumor bed vs resection specimen sampling) with recurrence among patients who undergo surgical resection for OCSCC.

Design, setting, and participants: This was a retrospective study of patients who had undergone surgical resection of OCSCC between January 1, 2000, and December 31, 2021, at a tertiary-level academic institution. Patients were grouped by margin assessment method (tumor bed [defect] or resection specimen sampling). Of 223 patients with OCSCC, 109 patients had localized tumors (pT1-T2, cN0), 154 had advanced tumors, and 40 were included in both cohorts. Disease recurrence after surgery was estimated by the cumulative incidence method and compared between cohorts using hazard ratios (HRs). Data analyses were performed from January 5, 2023, to April 30, 2023.

Main outcome and measures: Recurrence-free survival (RFS).

Results: The study population comprised 223 patients (mean [SD] age, 62.7 [12.0] years; 88 (39.5%) female and 200 [90.0%] White individuals) of whom 158 (70.9%) had defect-driven and 65 (29.1%) had specimen-driven margin sampling. Among the 109 patients with localized cancer, intraoperative positive margins were found in 5 of 67 (7.5%) vs 8 of 42 (19.0%) for defect- vs specimen-driven sampling, respectively. Final positive margins were 3.0% for defect- (2 of 67) and 2.4% for specimen-driven (1 of 42) margin assessment. Among the 154 patients with advanced cancer, intraoperative positive margins were found in 29 of 114 (25.4%) vs 13 of 40 (32.5%) for defect- and specimen-driven margins, respectively. Final positive margins were higher in the defect-driven group (9 of 114 [7.9%] vs 1 of 40 [2.5%]). When stratified by margin assessment method, the 3-year rates of local recurrence (9.7% vs 5.1%; HR, 1.37; 95% CI, 0.51-3.66), regional recurrence (11.0% vs 10.4%; HR, 0.85; 95% CI, 0.37-1.94), and distant recurrence (6.4% vs 5.0%; HR, 1.10; 95% CI, 0.36-3.35) were not different for defect- vs specimen-driven sampling cohorts, respectively. The 3-year rate of any recurrence was 18.9% in the defect- and 15.2% in the specimen-driven cohort (HR, 0.93; 95% CI, 0.48-1.81). There were no differences in cumulative incidence of disease recurrence when comparing defect- vs specimen-driven cases.

Conclusions and relevance: The findings of this retrospective cohort study indicate that margin assessment methods using either defect- or specimen-driven sampling did not demonstrate a clear association with the risk of recurrence after OCSCC resection. Specimen-driven sampling may be associated with reduced surgical margin positivity rates, which often necessitate concurrent chemotherapy with adjuvant radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Koyfman reported serving on the advisory boards of Merck, Regeneron, Galera DX, and Castle Biosciences; research support from Merck, Bristol Myers Squibb, Regeneron, and Castle Biosciences; and honoraria from UpToDate outside of the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Cumulative Incidence of Disease Recurrence Among Patients With OCSCC Who Underwent Resection, by Margin Assessment Method (Tumor Bed/Defect-Driven or Resection Specimen-Driven Sampling) and Tumor Severity
A, Both study groups and both margin assessment methods. B, Both study groups, stratified by margin assessment method. C, Patients with localized (pT1-T2, cN0) OCSCC, stratified by margin assessment method. D, Patients with OCSCC requiring adjuvant radiation therapy (pT1-T4, cN0-2), stratified by margin assessment strategy. OCSCC refers to oral cavity squamous cell carcinoma.
Figure 2.
Figure 2.. Margin Revision and Final Margin Status Among Patients With OCSCC Who Underwent Resection, by Tumor Severity and Margin Assessment Method
A, Localized (pT1-T2, cN0) OCSCC. B, Advanced (pT1-T4, cN0-2) OCSCC. DF refers to distant failure; LR, local recurrence; OCSCC, oral cavity squamous cell carcinoma; and RR, regional recurrence.

Similar articles

Cited by

References

    1. Varvares MA, Walker RJ, Chiosea S. Does a specimen-based margin analysis of early tongue cancer better predict local control? Laryngoscope. 2016;126(11):2426-2427. doi:10.1002/lary.26081 - DOI - PubMed
    1. Liu SW, Woody NM, Wei W, et al. . Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: multi-institutional oral cavity collaboration study. Head Neck. 2021;43(1):60-69. doi:10.1002/hed.26454 - DOI - PubMed
    1. Meier JD, Oliver DA, Varvares MA. Surgical margin determination in head and neck oncology: current clinical practice; the results of an International American Head and Neck Society Member Survey. Head Neck. 2005;27(11):952-958. doi:10.1002/hed.20269 - DOI - PubMed
    1. Hinni ML, Ferlito A, Brandwein-Gensler MS, et al. . Surgical margins in head and neck cancer: a contemporary review. Head Neck. 2013;35(9):1362-1370. doi:10.1002/hed.23110 - DOI - PubMed
    1. Prabhu AV, Sturgis CD, Lai C, et al. . Improving margin revision: characterization of tumor bed margins in early oral tongue cancer. Oral Oncol. 2017;75:184-188. doi:10.1016/j.oraloncology.2017.10.013 - DOI - PMC - PubMed

Publication types